Journal: Molecules

Article Title: New Biscoumarin Derivatives: Synthesis, Crystal Structure, Theoretical Study and Antibacterial Activity against Staphylococcus aureus

doi: 10.3390/molecules191219868

Figure Lengend Snippet: MIC of compounds 1 – 5 and antibiotics in Mueller-Hinton Broth Culture.

Article Snippet: Four S. aureus bacterial strains, including one drug-sensitive S. aureus ( S. aureus ATCC 29213) strain and three MRSA strains (MRSA XJ 75302, Mu50, USA 300 LAC), were used in the systematic analysis of the antibacterial activities of compounds 1 – 5 in vitro .

Techniques:

Journal: Molecules

Article Title: New Biscoumarin Derivatives: Synthesis, Crystal Structure, Theoretical Study and Antibacterial Activity against Staphylococcus aureus

doi: 10.3390/molecules191219868

Figure Lengend Snippet: Concentration-dependent inhibition of compound 1 on the growth of S. aureus ATCC 29213, MRSA XJ 75302, Mu50, and MRSA USA 300 LAC. The cells were cultured in liquid culture medium and treated with different concentrations of compound 1 .

Article Snippet: Four S. aureus bacterial strains, including one drug-sensitive S. aureus ( S. aureus ATCC 29213) strain and three MRSA strains (MRSA XJ 75302, Mu50, USA 300 LAC), were used in the systematic analysis of the antibacterial activities of compounds 1 – 5 in vitro .

Techniques: Concentration Assay, Inhibition, Cell Culture

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 1. Effect of vancomycin treatment on biofilm formation. Vancomycin significantly promoted biofilm formation in strains SJC1200 and Mu50. Strain SA113 was used as a biofilm-positive control. Adherent cells were stained with safranin and quantified by measuring the A490 nm. Numerals in brackets represent vancomycin concentrations used to treat Mu50. Van, vancomycin. *P < 0.05.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques: Positive Control, Staining

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 2. SEM of static biofilm formation. Biofilm formation by strains with or without vancomycin treatment in strains SJC1200 and Mu50. Vancomycin concentrations used to treat SJC1200 and Mu50 were 64 and 4 lg mL1, respectively. Photographs were taken at magnifications as indicated.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques:

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 3. Bacterial live/dead staining and CLSM of static biofilms. Biofilm formation in strains SJC1200 and Mu50 with or without vancomycin treatment was observed under (a) the time course of the bacterial live/dead staining and (b) CLSM. Vancomycin concentrations were the same as in Fig. 2. Photographs were taken at a magnification of 9400.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques: Staining

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 4. Detection of the changes in the transcription levels of selected biofilm-associated genes by qRT-PCR. Following vancomycin treatment, transcription levels of icaA, icaR, fnbA, spa, cidA, and lrgA were investigated over a time course by qRT-PCR in strains (a) SJC1200 or (b) Mu50. The fold change of each transcript was compared with vancomycin-untreated samples at each time point. *P < 0.05; **P < 0.001.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques: Quantitative RT-PCR

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 5. Effect of vancomycin on PIA synthesis. Time course of PIA production in strains SJC1200, SJC1201, and Mu50 with or without vancomycin treatment. SA113 was used as a PIA-positive control.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques: Positive Control

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 6. Effect of protease on biofilm formation. Biofilm stability against proteinase K or trypsin treatment in the presence or absence of vancomycin in strains SJC1200 and Mu50.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques:

Journal: FEMS Immunology & Medical Microbiology

Article Title: Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus aureus

doi: 10.1111/j.1574-695x.2011.00846.x

Figure Lengend Snippet: Fig. 7. Effects of eDNA and different antibiotics on biofilm formation. (a) The effect of eDNA extracted from Enterococcus faecalis and human monocytes on biofilm formation in strains SA113, SJC1200, and Mu50. Treatments with DNase I, eDNA, and vancomycin are indicated. EfDNA and HmDNA: genomic DNA from Enterococcus faecalis and human monocyte. #Treatment of DNase I to the established biofilm for 1 h. (b) The effect of vancomycin and eDNA on biofilm formation of a cidA-deficient strain SJC1201. SJC1200 was used as a control. The treatment of vancomycin and EfDNA is indicated. (c) The effect of antibiotics with distinct modes of action on biofilm formation in strain Mu50. AM, ampicillin; OX, oxacillin; KA, kanamycin; CIP, ciprofloxacin; CS, colistin; SPC, spectinomycin. Numerals adjacent to each antibiotic denote the concentration used in this study. *P < 0.05.

Article Snippet: Bacterial strains and plasmids used in this study Strain or plasmid Description Reference or source Strains Escherichia coli DH5a General molecular cloning and plasmids reservation Invitrogen Enterococcus faecalis HIP12467 pAM830::Tn1546; VanR NARSA, Flannagan et al. (2003) Staphylococcus aureus RN4220 Plasmids reservation NARSA SA113 PIA-producing control strain Kristian et al. (2004) ATCC 12598 Standard strain ATCC Mu50 Vancomycin-intermediate S. aureus (VISA) strain NARSA SJC1200 ATCC 12598/pG1546; VanR This study SJC1201 SJC1200, DcidA::spc; VanR, SpcR This study STA173 Clinical isolate; Van MIC = 2 lg mL 1 CGMH STA198 Clinical isolate; Van MIC = 1.5 lg mL 1 CGMH Plasmids pGHL6 E. coli/S. aureus shuttle vector Lin et al. (1999) pG1546 pGHL6/DluxAB::van operon This study pMAD Vector for allelic replacement Arnaud et al. (2004) pMAcid pMAD/cidA::spc This study VanR, vancomycin resistant; SpcR, spectinomycin resistant; NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus; CGMH, Chang Gung Memorial Hospital.

Techniques: Control, Concentration Assay

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Discovery of N -quinazolinone-4-hydroxy-2-quinolone-3-carboxamides as DNA gyrase B-targeted antibacterial agents

doi: 10.1080/14756366.2022.2084088

Figure Lengend Snippet: Antibacterial activity of f1 and its derivatives, f4 and f14 , against a panel of S. aureus strains.

Article Snippet: The MIC value of compound f1 ( 4–8 μg/mL ) was close to that of vancomycin (0.5–1 μg/mL), and thus, we further tested f1 against a panel of MRSA strains (ATCC 33591, ATCC 43300, 18–2) and vancomycin-intermediate-resistant S. aureus (VISA) strains (ATCC 700699, HIP 5836, and HIP 5827).

Techniques: Activity Assay